Vaccines make good immune theater: Immunization as described in a three-act play

Infectious Diseases in Clinical Practice

Volumn 14, Issue 1, 2006, Pages 35-45

  Rosenthal, Ken S ^a  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACELLULAR VACCINE; ALUMINUM POTASSIUM SULFATE; CHICKENPOX VACCINE; CYTOKINE; DIPHTHERIA VACCINE; DNA VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN M; INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE VACCINE; LYME DISEASE VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN; MEASLES VACCINE; MENINGOCOCCUS VACCINE; MONTANIDE ISA51; MUMPS VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; PERTUSSIS VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; RABIES VACCINE; ROTAVIRUS VACCINE; SMALLPOX VACCINE; TETANUS TOXOID; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS VACCINE; YELLOW FEVER VACCINE;

ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE ACTIVATION; BCG VACCINATION; CANCER CONTROL; CANCER IMMUNIZATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHICKENPOX; CLINICAL TRIAL; COMPLEMENT SYSTEM; DENDRITIC CELL; DIPHTHERIA; DRUG TARGETING; HEPATITIS A; HEPATITIS B; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNIZATION; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; IMMUNOPROPHYLAXIS; IMMUNOREACTIVITY; IMMUNOSTIMULATION; INFECTION CONTROL; INFLUENZA; INFLUENZA VACCINATION; INNATE IMMUNITY; LYME DISEASE; LYMPH NODE; MACROPHAGE; MAJOR HISTOCOMPATIBILITY COMPLEX; MASS IMMUNIZATION; MEASLES; MEASLES VACCINATION; MEDICAL PRACTICE; MENINGOCOCCOSIS; MUMPS; NATURAL KILLER CELL; NONHUMAN; PERFORMING ARTS; PERTUSSIS; POLIOMYELITIS; RABIES; RUBELLA; SMALLPOX; STREPTOCOCCUS INFECTION; T LYMPHOCYTE ACTIVATION; TETANUS; TETANUS PROPHYLAXIS; TH1 CELL; TH2 CELL; VACCINATION; VIRUS INFECTION; YELLOW FEVER;

EID: 33646518446     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.idc.0000201779.55618.1b     Document Type: Article

References (16)

1. Levine MM, Woodrow GC, Kaper JB. New Generation Vaccines. 2nd ed. New York, NY: Marcel Dekker; 1997.
2. Plotkin SA, Orenstein WA, Offit PA. Vaccines. 4th ed. Philadelphia, Pa: Saunders; 2004.
3. Netea MG, Van der Meer JWM, Sutmuller RP, et al. From the Th1/Th2 Paradigm towards a Toll-Like Receptor/T-Helper Bias. Antimicrob Agents Chemother. 2005;49:3991-3996.
4. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003;3:133-146.
5. Hopkins PA, Sriskandan S. Mammalian Toll-like receptors: to immunity and beyond. J Clin Exp Immunol. 2005;140:395-407.
6. Kapsenberg ML. Dendritic cell control of pathogen-driven T-cell polarization. Nat Rev Immunol. 2003;3:984-993.
7. Kopp E, Medzhitov R. Recognition of microbial infection by Toll-like receptors. Curr Opin Immunol. 2003;15:396-401.
8. Palucka K, Banchereau J. How dendritic cells and microbes interact to elicit or subvert protective immune responses. Curr Opin Immunol. 2002;14:420-431.
9. Medzhitov R, Janeway CA Jr. Decoding the patterns of self and nonself by the innate immune system. Science. 2002;296:298-300.
10. Rosenthal KS. Are microbial symptoms "self-inflicted"? The consequences of immunopathology. Infect Dis Clin Prac. 2005;13:306-310.
11. Rosenthal KS. Immune peptide enhancement of peptide based vaccines. Front Biosci. 2005;10:478-482.
12. Goel N, Zimmerman DH, Rosenthal KS. Ligand epitope antigen presentation system vaccines against herpes simplex virus. Front Biosci. 2005;10:966-974.
13. Zimmerman DH, Rosenthal KS. The L.E.A.P.S. approach to vaccine development. Front Biosci. 2005;10:790-798.
14. Rosenthal KS, Mao HW, Home WI, et al. Immunization with a L.E.A.P.S. heteroconjugate containing a CTL epitope and a peptide from beta-2-microglobulin elicits a protective and DTH response to herpes simplex virus type 1. Vaccine. 1998;17:535-542.
15. Goel N, Rong Q, Zimmerman D, et al. A L.E.A.P.S. heteroconjugate vaccine containing a T cell epitope from HSV-1 glycoprotein D elicits Th1 responses and protection. Vaccine. 2003;21:4410-4420.
16. Bedrosian I, Mick R, Xu S, et al. Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients. J Clin Oncol. 2003;21:3826-3835.